CBAY - CymaBay announces result from two-year study of primary biliary cholangitis therapy

CymaBay Therapeutics (NASDAQ:CBAY -4.3%) said on Monday that results from a new analyses of clinical studies showed that seladelpar treatment through two years resulted in a decrease in Primary Biliary Cholangitis globe score and predicted improved transplant-free survival. The company said treatment of 50 patients with oral seladelpar 5 mg or 10 mg daily for two years resulted in a mean change from baseline in globe score of -0.417. A globe score above > 0.3 has significant risk for needing a liver transplant or death, whereas a score ? 0.3 has a risk that can’t be distinguished from a matched population. The improvement in globe score and predicted survival did not depend on age, the company said. Last month, the company announced positive data from a mid-stage study which examined the efficacy and safety of seladelpar in adults with PBC who were receiving or intolerant to first-line therapy with ursodeoxycholic acid.

For further details see:

CymaBay announces result from two-year study of primary biliary cholangitis therapy